What is in the GLOW blend, how each of its three peptides is studied in the laboratory literature, how a blend is documented on its certificate of analysis, and how GLOW differs from the KLOW blend.
Part of the PeptidesATX Research Hub
GLOW is a three-peptide research blend supplied as a single lyophilised powder in a sealed glass vial, 70 mg labeled content. The composition below is the composition on the certificate of analysis: each component is measured separately against its labeled amount on every released lot.
| Component | Labeled amount |
|---|---|
| Body Protection Compound 157 | 10 mg |
| TB | 10 mg |
| GHK | 50 mg |
The KLOW blend is GLOW plus KPV: the three components here are present at the same labeled amounts in both, and KPV is the only difference. The current lot, its purity and net content, the measured content of each component, and links to the certificate and endotoxin report are on the GLOW Blend 70mg product page.
Everything sold on this site is for laboratory research use only. This guide describes composition and the published laboratory literature; it does not describe or recommend any use of these compounds.
Body Protection Compound 157 is a synthetic 15-residue peptide (C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0) whose sequence is derived from a protein found in gastric juice. The laboratory literature studies it in cell culture and animal models for cytoprotective signalling, angiogenesis-related pathways including nitric-oxide and growth-factor systems, and tissue-repair models (Sikiric et al., Curr Neuropharmacol 2016; Chang et al., J Appl Physiol 2011). It is noted for stability across a range of pH conditions.
TB is a 43-residue peptide of the thymosin family (C212H350N56O78S, 4,963 g/mol) and a major actin-sequestering peptide in mammalian cells. It is studied for its role in actin dynamics, cell migration, endothelial-cell behaviour and wound-model biology (Goldstein et al., Trends Mol Med 2005; Malinda et al., J Invest Dermatol 1999; Philp et al., Wound Repair Regen 2003). At 4,963 g/mol it is the largest molecule in the blend.
GHK is the tripeptide glycyl-histidyl-lysine (C14H24N6O4, 340.38 g/mol, CAS 49557-75-7), supplied in this blend as its copper complex (402.92 g/mol), which is how it occurs in plasma. It is studied for copper-dependent gene-expression changes, collagen and extracellular-matrix remodelling, and responses to oxidative stress in fibroblast and skin-model systems (Pickart and Margolina, Int J Mol Sci 2018; Pickart, J Biomater Sci Polym Ed 2008). At 50 mg it is the largest component by mass.
The components act through non-overlapping pathways in the literature — cytoprotective and growth-factor signalling, actin dynamics and cell migration, and copper-dependent matrix biology. A pre-mixed blend exists so a laboratory can expose one preparation to a model system and compare the result against the single-compound preparations, with the ratio between components held constant from vial to vial.
Whether the three behave differently together than apart is a question for the experiment, not a property of the product. The published work on each compound is on the compound alone; this guide makes no claim about combined effects. Combination studies need controls for each single component so that a combination-specific response can be distinguished from an additive one.
One certificate of analysis covers the vial. For a blend it reports:
A separate endotoxin report accompanies most lots (the current lot's documents are linked on the product page; some early-2026 lots have none, and the report states a result without naming the assay method). The certificates do not include heavy-metal, sterility, residual-solvent or microbial testing. The lot number printed on the vial is the lot number on the certificate, so a certificate can be matched to the material in hand. Certificates for every released lot are on the COA page.
Sealed vials are kept cold, dry and protected from light, and frozen for long-term storage. The blend is supplied as lyophilised powder and is reconstituted with bacteriostatic water for laboratory handling; the reconstitution guide covers the general procedure.
| GLOW Blend 70mg | KLOW Blend 80mg | |
|---|---|---|
| Components | Body Protection Compound 157 · TB · GHK | Body Protection Compound 157 · TB · GHK · KPV |
| Labeled amounts | 10 mg · 10 mg · 50 mg | 10 mg · 10 mg · 50 mg · 10 mg |
| Fourth component | None | KPV, a melanocortin-derived tripeptide |
| Certificate | Per-component measured content on one certificate | Per-component measured content on one certificate |
The full comparison, including what the fourth component adds to a study design, is in GLOW vs KLOW: What the Fourth Component Changes.
GLOW is a three-peptide research blend: Body Protection Compound 157 (10 mg), TB (10 mg) and GHK supplied as its copper complex (50 mg) in one lyophilised vial, 70 mg labeled content. Each component is measured separately on the lot's certificate of analysis.
Body Protection Compound 157, a 15-residue synthetic peptide derived from a gastric-juice protein; TB, a 43-residue actin-binding peptide of the thymosin family; and GHK, a copper-binding tripeptide supplied as its copper complex.
KLOW is GLOW plus 10 mg of KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. The three shared components are present at the same labeled amounts in both; GLOW's labeled content is 70 mg against KLOW's 80 mg.
Each is studied on its own in cell culture and animal models: Body Protection Compound 157 for cytoprotective and growth-factor signalling, TB for actin dynamics and cell migration, and GHK for copper-dependent gene expression and extracellular-matrix remodelling. The blend lets a laboratory compare one preparation against the single components; the guide makes no claim about combined effects, and nothing here describes effects in people.
One certificate covers the vial. It reports identity and purity by UPLC/MS, net content measured against the 70 mg labeled amount, and the measured content of each of the three components. A separate endotoxin report accompanies most lots (it states a result but not the assay method, and the certificate does not include heavy-metal, sterility, residual-solvent or microbial testing); the current lot's documents are linked from the product page.
Identity and purity of the blend by UPLC/MS, measured content of each component against its labeled amount, an endotoxin result, and a lot number on the vial that matches the certificate. The current lot's certificate and endotoxin report are on the product page; every released lot is on the COA page.
The current lot's certificate, endotoxin report and per-component measured content are on the product page.
GLOW Blend 70mg Certificates of Analysis GLOW vs KLOWDisclaimer: The compounds described are intended for laboratory research use only and are not approved for human or veterinary use. This article describes composition and published laboratory literature; it makes no claims about any compound's effects in people and does not describe or recommend any use, administration or dosing of any compound.